Clinical trials
Completed Phase 4 trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
985 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 3 |
| 2002 | 20 |
| 2003 | 37 |
| 2004 | 45 |
| 2005 | 55 |
| 2006 | 80 |
| 2007 | 62 |
| 2008 | 56 |
| 2009 | 72 |
| 2010 | 59 |
| 2011 | 56 |
| 2012 | 53 |
| 2013 | 52 |
| 2014 | 56 |
| 2015 | 58 |
| 2016 | 45 |
| 2017 | 34 |
| 2018 | 29 |
| 2019 | 32 |
| 2020 | 19 |
| 2021 | 23 |
| 2022 | 16 |
| 2023 | 7 |
| 2024 | 2 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 985 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 70 |
| University Hospital, Clermont-Ferrand | 31 |
| University Hospital, Toulouse | 29 |
| Hoffmann-La Roche | 28 |
| Pfizer | 26 |
| Novartis Pharmaceuticals | 24 |
| Sanofi | 22 |
| Boehringer Ingelheim | 21 |
| Eli Lilly and Company | 19 |
| Bayer | 18 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 36 |
| Diabetes Mellitus | 25 |
| Arthritis, Rheumatoid | 23 |
| Multiple Sclerosis | 21 |
| Coronary Artery Disease | 20 |
| Pain | 19 |
| Hypertension | 18 |
| Pulmonary Disease, Chronic Obstructive | 17 |
| Asthma | 15 |
| Agnosia | 14 |
Trials
Showing 1 to 25 of 985. Each trial links to its page on Pharma Observatory.
885 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.